Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
OrbusNeich today announced that it has filed a lawsuit in the Netherlands against Dr. Pavel Cervinka and Masaryk Hospital in Usti nad Labem, Czech...
OrbusNeich today announced the launch of the CE marked Azule Cobalt Chromium Stent. The Azule Stent combines the proven stent design of its...
OrbusNeich today announced that the next-generation Sapphire II coronary dilatation catheter is now commercially available, following CE Mark...
OrbusNeich today announced that 12-month follow-up data from the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth)...
Data from patients who are considered high-risk due to underlying clinical conditions and who cannot be treated with drug eluting stents (DES) and...
OrbusNeich today announced that the United States Patent and Trademark Office (USPTO) has granted an additional patent expanding protection of the...
OrbusNeich's Genous Stent shows favorable outcomes compared to bare metal stents (BMS) for the treatment of coronary artery bifurcation lesions,...
OrbusNeich today announced that data from two studies demonstrate that the Genous Stent increases endothelial coverage and reduces thrombogenicity as ...
OrbusNeich today reported the completion of patient enrollment in a randomized clinical study of its Genous Bio-engineered R stent at 11 sites in...
OrbusNeich today announced that clinical trial results highlighting the company's Genous Bio-engineered R stent and its endothelial progenitor cell...
OrbusNeich today announced at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 in Washington the completion of patient enrollment in the...
OrbusNeich today announced that six-month follow-up clinical trial data demonstrate the excellent safety profile and efficacy of the company's Genous ...
OrbusNeich today reported that optical coherence tomography (OCT) evaluation of a patient with anterior ST-elevation myocardial infarction (STEMI)...
OrbusNeich today announced that six-month clinical follow-up data show the safety and efficacy of the combination of pre-dilatation with a paclitaxel ...
OrbusNeich today announced that 12-month follow-up data from a subset analysis of the global e-HEALING registry demonstrate that the company's Genous ...
OrbusNeich today announced that a subset analysis of patients over 70 years of age in the final 12-month clinical results of the global e-HEALING...
OrbusNeich announced that following CE Mark (Conformite Europeenne) approval, its Genous Bio-engineered Cobalt Chromium Stent is now commercially...
OrbusNeich today announced that 12 month follow up data from real world patients demonstrated long term clinical efficacy of the company's Genous...
OrbusNeich announced that clinical data presented at the Joint Intervention Meeting (JIM) 2010 in Rome provide further evidence that the company's...
OrbusNeich today announced that the first patient has been enrolled in a randomized clinical trial of the Genous Bio-engineered R stent in China. A...
OrbusNeich announced today that data published in EuroIntervention (EuroIntervention, 2010; 5:698-702) demonstrated good safety and efficacy, low...
OrbusNeich announced that clinical data presented today at Asia PCR/Singapore LIVE 2010 demonstrated the benefits of the Genous Bio-engineered R...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.